Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Rimvydas Šlapikas:

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Catapano AL et al. Eur Heart J. (2016)

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. Schwartz GG et al. N Engl J Med. (2018)

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. Ridker PM et al. N Engl J Med. (2017)

Search results

Items: 1 to 20 of 45

1.

Corrigendum to "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205].

Task Force Members; ESC National Cardiac Societies; ESC Committee for Practice Guidelines (CPG).

Atherosclerosis. 2019 Dec 20. pii: S0021-9150(19)31611-9. doi: 10.1016/j.atherosclerosis.2019.12.004. [Epub ahead of print] No abstract available.

PMID:
31870624
2.

European Society of Cardiology: Cardiovascular Disease Statistics 2019.

Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, Mossialos EA, Maggioni AP, Kazakiewicz D, May HT, De Smedt D, Flather M, Zuhlke L, Beltrame JF, Huculeci R, Tavazzi L, Hindricks G, Bax J, Casadei B, Achenbach S, Wright L, Vardas P; European Society of Cardiology .

Eur Heart J. 2020 Jan 1;41(1):12-85. doi: 10.1093/eurheartj/ehz859.

PMID:
31820000
3.

Erratum to "2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205].

Authors/Task Force Members; ESC National Cardiac Societies; ESC Committee for Practice Guidelines (CPG).

Atherosclerosis. 2020 Jan;292:160-162. doi: 10.1016/j.atherosclerosis.2019.11.020. Epub 2019 Dec 4. No abstract available.

PMID:
31811963
4.

Cohort profile The ESC-EORP Chronic Ischemic Cardiovascular Disease Long-Term (CICD LT) registry.

Komajda M, Cosentino F, Ferrari R, Laroche C, Maggioni A, Steg PG, Tavazzi L, Kerneis M, Valgimigli M, Gale CP; CICD investigators group .

Eur Heart J Qual Care Clin Outcomes. 2019 Oct 11. pii: qcz057. doi: 10.1093/ehjqcco/qcz057. [Epub ahead of print]

PMID:
31605146
5.

2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.

Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies.

Atherosclerosis. 2019 Nov;290:140-205. doi: 10.1016/j.atherosclerosis.2019.08.014. Epub 2019 Aug 31. No abstract available. Erratum in: Atherosclerosis. 2020 Jan;292:160-162. Atherosclerosis. 2019 Dec 20;:.

6.

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group .

Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455. No abstract available.

PMID:
31504418
7.

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.

Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators.

Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Erratum in: Lancet Diabetes Endocrinol. 2019 Jul 8;:. Lancet Diabetes Endocrinol. 2019 Sep;7(9):e21.

PMID:
31272931
8.

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators.

N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7.

PMID:
30403574
9.

The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up.

Komajda M, Kerneis M, Tavazzi L, Balanescu S, Cosentino F, Cremonesi A, Ferrari R, Kownator S, Szwed H, Mintale I, Olivari Z, Rittger H, Shlyakhto EV, Slapikas R, Steg PG, Valgimigli M, Van Belle E, Tsioufis K, Majda W, Laroche C, Maggioni AP; ESC–CICD Pilot Registry Investigators.

Eur J Prev Cardiol. 2018 Mar;25(4):377-387. doi: 10.1177/2047487317751955. Epub 2018 Jan 16.

PMID:
29338315
10.

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group.

N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.

11.

Dobutamine-stress echocardiography speckle-tracking imaging in the assessment of hemodynamic significance of coronary artery stenosis in patients with moderate and high probability of coronary artery disease.

Rumbinaitė E, Žaliaduonytė-Pekšienė D, Vieželis M, Čeponienė I, Lapinskas T, Žvirblytė R, Venclovienė J, Morkūnaitė K, Bielinis A, Šlapikas R, Vaškelytė JJ.

Medicina (Kaunas). 2016;52(6):331-339. doi: 10.1016/j.medici.2016.11.005. Epub 2016 Nov 25.

12.

Early and late diastolic strain rate vs global longitudinal strain at rest and during dobutamine stress for the assessment of significant coronary artery stenosis in patients with a moderate and high probability of coronary artery disease.

Rumbinaite E, Zaliaduonyte-Peksiene D, Lapinskas T, Zvirblyte R, Karuzas A, Jonauskiene I, Viezelis M, Ceponiene I, Gustiene O, Slapikas R, Vaskelyte JJ.

Echocardiography. 2016 Oct;33(10):1512-1522. doi: 10.1111/echo.13282. Epub 2016 Jun 16.

PMID:
27307201
13.

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT; ESC Scientific Document Group.

Eur Heart J. 2016 Oct 14;37(39):2999-3058. doi: 10.1093/eurheartj/ehw272. Epub 2016 Aug 27. No abstract available.

14.

Clinical relevance of high sensitivity C-reactive protein in cardiology.

Adukauskienė D, Čiginskienė A, Adukauskaitė A, Pentiokinienė D, Šlapikas R, Čeponienė I.

Medicina (Kaunas). 2016;52(1):1-10. doi: 10.1016/j.medici.2015.12.001. Epub 2016 Jan 15. Review.

15.

EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT).

Komajda M, Weidinger F, Kerneis M, Cosentino F, Cremonesi A, Ferrari R, Kownator S, Steg PG, Tavazzi L, Valgimigli M, Szwed H, Majda W, Olivari Z, Van Belle E, Shlyakhto EV, Mintale I, Slapikas R, Rittger H, Mendes M, Tsioufis C, Balanescu S, Laroche C, Maggioni AP.

Eur Heart J. 2016 Jan 7;37(2):152-60. doi: 10.1093/eurheartj/ehv437. Epub 2015 Sep 1.

16.

The fear of dying and occurrence of posttraumatic stress symptoms after an acute coronary syndrome: A prospective observational study.

Malinauskaite I, Slapikas R, Courvoisier D, Mach F, Gencer B.

J Health Psychol. 2017 Feb;22(2):208-217. doi: 10.1177/1359105315600233. Epub 2016 Jul 10.

PMID:
26311815
17.

Associations between risk factors in childhood (12-13 years) and adulthood (48-49 years) and subclinical atherosclerosis: the Kaunas Cardiovascular Risk Cohort Study.

Ceponiene I, Klumbiene J, Tamuleviciute-Prasciene E, Motiejunaite J, Sakyte E, Ceponis J, Slapikas R, Petkeviciene J.

BMC Cardiovasc Disord. 2015 Aug 18;15:89. doi: 10.1186/s12872-015-0087-0.

18.

Prognostic value of myocardial perfusion abnormalities for long-term prognosis in patients after coronary artery bypass grafting.

Milvidaite I, Kulakiene I, Vencloviene J, Kinduris S, Jurkiene N, Grizas V, Navickas R, Slapikas R.

Indian J Nucl Med. 2014 Oct;29(4):222-6. doi: 10.4103/0972-3919.142623.

19.

Prevalence of cardiovascular risk factors in Lithuanian middle-aged subjects participating in the primary prevention program, analysis of the period 2009-2012.

Laucevičius A, Rinkūnienė E, Skujaitė A, Petrulionienė Ž, Puronaitė R, Dženkevičiūtė V, Kasiulevičius V, Jatužis D, Ryliškytė L, Šlapikas R.

Blood Press. 2015 Feb;24(1):41-7. doi: 10.3109/08037051.2014.961744. Epub 2014 Sep 30.

PMID:
25268930
20.

Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): results of the Dyslipidemia International Study (DYSIS).

Viigimaa M, Erglis A, Latkovskis G, Mäeots E, Petrulionienė Ž, Šlapikas R, Gocentiene A, Bramlage P, Brudi P.

Medicina (Kaunas). 2014;50(1):44-53. doi: 10.1016/j.medici.2014.05.003. Epub 2014 Jun 10.

Supplemental Content

Loading ...
Support Center